---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OPERA-02"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OPERA-02. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 22 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence/opera-02"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OPERA-02

<a id="heading-3.1.5"></a>

## 3.1.5 OPERA-02

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Primary comparison

> “This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Registry dates and planned enrollment

| Item | Value |
| --- | --- |
| Study start (actual) | “2025-11-03” |
| Primary completion (estimated) | “2028-12” |
| Study completion (estimated) | “2032-01” |

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.2-2"></a>

#### Enrollment start

> “Enrollment began in November 2025.”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.2-3"></a>

#### Participating countries

> “Australia Austria Belgium Brazil Canada Chile Czechia France Germany Greece Hong Kong Hungary Israel Italy Malaysia Mexico The Netherlands The Philippines Poland Portugal Romania South Korea Spain Taiwan Thailand UK USA”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.2-4"></a>

#### Enrollment status

> “Enrollment is accelerating, investigator interest is strong, and patients with frontline disease continue to require better therapeutic options.”

Source: [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and)

<a id="topic-3.1.5.2-5"></a>

#### Anticipated top-line data

> “We anticipate top-line data in 2028 and, if successful, anticipate potential FDA approval and commercial launch in the frontline MBC setting in the United States in 2029.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Randomized, double-blind, active-controlled design

> “This is an international, multicenter, randomized, double-blind, active-controlled, phase 3 clinical trial.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.3-2"></a>

#### Stratification factors and randomization ratio

> “Menopausal status: post vs pre- or peri-/male”
> “Visceral metastasis: yes vs no”
> “De novo metastatic disease vs recurrent disease after adjuvant ET”
> “Geographical region: US, Canada and Australia vs Europe vs Other”
> “1:1”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Key inclusion criteria

> “Newly diagnosed advanced breast cancer or disease recurrence occurring after 12 months of completing adjuvant endocrine therapy with or without CDK4/6 inhibitor”
> “Evaluable disease (measurable disease or evaluable bone disease)”
> “Female participants can be pre-, peri-, or post-menopausal”
> “Male and pre- or peri-menopausal female participants must be willing to take a gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) agonist”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.4-2"></a>

#### Key exclusion criteria

> “Disease recurrence during or within 12 months of completing adjuvant endocrine therapy”
> “Prior treatment with a SERD or any investigational endocrine therapy”
> “Active or symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.4-3"></a>

#### Prior endocrine therapy exclusions in the registry record

> “Previously received treatment with fulvestrant, elacestrant or an investigational endocrine therapy in any setting.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Investigational and control regimens

> “Palazestrant 90 mg QD and letrozole-matching placebo QD on days 1-28; ribociclib 600 mg QD on days 1-21.”
> “Letrozole 2.5 mg QD and palazestrant-matching placebo QD on days 1-28; ribociclib 600 mg QD on days 1-21.”

Source: [Tolaney et al. (2025)](https://ir.olema.com/static-files/e5b62d98-7b5b-46fa-9d9a-bbc378f6749b)

<a id="topic-3.1.5.5-2"></a>

#### Selection of the 90 mg dose

> “The FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial in frontline ER+/HER2- metastatic breast cancer.”

Source: [Olema Oncology dose selection announcement (2025)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-palazestrant-dose-selection-and-trial)

<a id="topic-3.1.5.5-3"></a>

#### Ribociclib supply

> “Under the terms of the agreement, Novartis will provide Olema with ribociclib drug supply for the planned, Olema-sponsored, Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in ER+/HER2- frontline advanced or metastatic breast cancer.”

Source: [Olema Oncology Novartis OPERA-02 agreement announcement (2024)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-new-clinical-trial-collaboration-and)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Investigator-assessed Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Primary, key secondary, and other secondary endpoints

| Endpoint role | Endpoint |
| --- | --- |
| Primary endpoint | “PFS, as assessed by local investigator” |
| Key secondary endpoint | “OS” |
| Other secondary endpoint | “PFS (per BIRC)” |
| Other secondary endpoint | “ORR, CBR, and DOR (per local investigator and BIRC)” |
| Other secondary endpoint | “PFS2” |
| Other secondary endpoint | “Safety and tolerability” |
| Other secondary endpoint | “PK” |
| Other secondary endpoint | “Patient-reported outcomes” |

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="topic-3.1.5.6.1-2"></a>

##### Registry definition of the primary outcome

> “To compare PFS, based on a local investigator assessment, between investigational (palazestrant with ribociclib + letrozole-matching placebo) and control (letrozole with ribociclib + palazestrant-matching placebo) arms.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.6.1-3"></a>

##### Patient-reported outcomes as a secondary endpoint

> “To evaluate the change from baseline in health-related PROs assessed using standardized instruments that are widely used in (breast) cancer clinical trials”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.6.1-4"></a>

##### Regulatory rationale for progression-free survival

> “PFS can reflect tumor growth”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Planned randomization

> “Approximately 1,000 participants will be randomized in a 1:1 ratio to one of the two study arms.”

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767)

<a id="topic-3.1.5.7.1-2"></a>

##### Planned participants per arm

> “n ≈ 500”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

No results from OPERA-02 have been reported; primary completion is estimated for December 2028, and top-line data are anticipated in 2028. The trial enrolls participants with no prior systemic therapy for advanced breast cancer and tests palazestrant in combination with ribociclib, so its population and regimen are outside this indication of previously treated disease and palazestrant monotherapy. The primary endpoint is investigator-assessed PFS, with PFS by blinded independent central review as a secondary endpoint. Participants previously treated with fulvestrant, elacestrant, or an investigational endocrine therapy in any setting are excluded.

Source: [ClinicalTrials.gov NCT07085767](https://clinicaltrials.gov/study/NCT07085767); [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf); [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-3.1.5.9-2"></a>

#### First-line population outside the previously treated indication

> “No prior systemic therapy for ABC”

Source: [Tolaney et al. (2026)](https://olema.com/wp-content/uploads/2026/05/ASCO-2026-OPERA-02-TiP-Poster_FINAL.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
